Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04905407 · ClinicalTrials.gov registry record · Phase 2
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase 2 study, sponsored by Syros Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT04905407 is a Phase 2 study that was terminated before completion, run by Syros Pharmaceuticals. The registered enrollment target is 66 participants.
The verdict
NCT04905407, a Phase 2 study, was terminated before completion, sponsored by Syros Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
Tamibarotene is being studied as a treatment for participants with a type of leukemia called acute myeloid leukemia, or AML for short. Tamibarotene is being studied as a treatment for participants with AML whose cancer has a specific genetic abnormality characterized by the overexpression of the retinoic acid receptor alpha (RARA) gene. This genetic profile is found in about 3 of every 10 people with AML. During the trial, tamibarotene will be given with 2 other drugs that are already used together to treat people who have AML and who cannot start treatment with standard chemotherapy.
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG Tamibarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2021-08-26 |
| Est. Completion | 2024-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04905407
The ClinicalTrials.gov registry entry for NCT04905407 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syros Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT04905407 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04905407 about?
NCT04905407 is a clinical study titled "Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)". Tamibarotene is being studied as a treatment for participants with a type of leukemia called acute myeloid leukemia, or AML for short. Tamibarotene is being studied as a treatment for participants with AML whose cancer has a specific genetic abnormality characterized by the overexpression of the ret...
What is the current status of trial NCT04905407?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2021-08-26. Estimated completion is 2024-08-12.
What interventions are being tested in trial NCT04905407?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Tamibarotene (DRUG).
Who is sponsoring clinical trial NCT04905407?
This trial is sponsored by Syros Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.